phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide has been researched along with angiotensin ii in 2 studies
| Studies (phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide) | Trials (phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide) | Recent Studies (post-2010) (phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide) | Studies (angiotensin ii) | Trials (angiotensin ii) | Recent Studies (post-2010) (angiotensin ii) |
|---|---|---|---|---|---|
| 276 | 0 | 55 | 38,152 | 1,089 | 7,413 |
| 7 | 0 | 5 | 38,152 | 1,089 | 7,413 |
| Protein | Taxonomy | phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide (IC50) | angiotensin ii (IC50) |
|---|---|---|---|
| Atrial natriuretic peptide receptor 3 | Homo sapiens (human) | 0.002 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.002 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0018 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0055 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.004 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.0011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harris, KH; Jhamandas, JH; Jhamandas, KH; Petrov, T; Yang, HY | 1 |
| Bernhardt, G; Biselli, S; Buschauer, A; Cabrele, C; Einsiedel, J; Gmeiner, P; Hübner, H; Keller, M; Kuhn, KK; Mollereau, C; Svobodová, J; Vanderheyden, PM; Wifling, D | 1 |
2 other study(ies) available for phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and angiotensin ii
| Article | Year |
|---|---|
Activation of neuropeptide FF neurons in the brainstem nucleus tractus solitarius following cardiovascular challenge and opiate withdrawal.
Topics: Angiotensin II; Animals; Hemodynamics; Hypertension; Hypotension; Male; Morphine; Morphine Dependence; Naloxone; Neurons; Nitroprusside; Oligopeptides; Phenylephrine; Rats; Rats, Sprague-Dawley; Shock, Hemorrhagic; Solitary Nucleus; Substance Withdrawal Syndrome | 1998 |
Mimicking of Arginine by Functionalized N(ω)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.
Topics: Angiotensin II; Arginine; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Ligands; Molecular Structure; Neuropeptide Y; Neurotensin; Oligopeptides; Peptide Fragments; Receptors, Angiotensin; Receptors, Neuropeptide; Receptors, Neurotensin; Structure-Activity Relationship | 2016 |